Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy

Quy Le, PhD, Sommer Castro, BS, Thao T. Tang, Anisha Loeb, BA, Amanda R. Leonti, MS, Laura Pardo, Michael R. Loken, PhD, Colin Correnti, PhD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-143140

Published: 2020

Journal Articles

Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol

Lisa Eidenschink Brodersen, PhD, Chad A. Hudson, MDPhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Laura Pardo, Amanda R. Leonti, MS, Timothy P. Singleton, MD, Fan-Chi Hsu, PhD, Loren L. Lott, Fangyan Dai, Keely Ghiradelli, E. Anders Kolb, MD, Todd M. Cooper, DO, Jessica A. Pollard, MD, Michael R. Loken, PhD, Richard Aplenc, MD PhD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-142659

Published: 2020

Journal Articles

CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia

Katherine Tarlock, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Yi-Cheng Wang, Robert B. Gerbing, Laura Pardo, Fangyan Dai, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Jessica A. Pollard, MD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 2699.

https://doi.org/10.1182/blood-2019-127100

Published: 2019

Journal Articles

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Adam J. Lamble, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Jim Wang, Robert B. Gerbing, Laura Pardo, Lillian Sung, MD PhD, Sarah K. Tasian, MD, Todd M Cooper, DO, E. Anders Kolb, MD, Richard Aplenc, MD PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 459.

https://doi.org/10.1182/blood-2019-124587

Published: 2019

Journal Articles

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031

Jessica A. Pollard, MD, Todd A. Alonzo, PhD, Patrick A. Brown, MD, Robert B. Gerbing, Elizabeth Fox, MD, John Kim Choi, MD, Brian T. Fisher, DO, MSCE, Betsy A Hirsch, PhD, Samir Kahwash, MD, John E. Levine, MDMS, Michael R. Loken, PhD, Susana C. Raimondi, PhD, Katherine Tarlock, MD, Andrew C. Wood, MBCHB, Lillian Sung, MD PhD, Anders E. Kolb, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD, Richard Aplenc, MD PhD

Blood (2019) 134 (Supplement_1): 292.

https://doi.org/10.1182/blood-2019-129557

Published: 2019

Journal Articles

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Johann K. Hitzler, MD, Jason Berman, MD, Robert B. Gerbing, Amy Beckman, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd E Druley, MD PhD, Michael R. Loken, PhD, Lisa Eidenschink Brodersen, PhD, Karen Chisholm, Shelton A. Viola, MD, Jeffrey W. Taub, MD, Alan S Gamis, MD MPH, Todd A. Alonzo, PhD, E. Anders Kolb, MD

Blood (2019) 134 (Supplement_1): 118.

https://doi.org/10.1182/blood-2019-126723

Published: 2019

Journal Articles

A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies

Hamid Bolouri, PhD, Benjamin K. Johnson, PhD, Rhonda E. Ries, MA, Laura Pardo, Tiffany A. Hylkema, BS, Wanding Zhou, PhD, Jenny L. Smith, MSc, MD, Amanda R. Leonti, MS, Allison Kaeding, MD, Michael R. Loken, PhD, Jason E. Farrar, MD, Soheil Meshinchi, MD PhD, Timothy Junius Triche, Jr., PhD

Blood (2019) 134 (Supplement_1): 3768.

https://doi.org/10.1182/blood-2019-123487

Published: 2019

Journal Articles

Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML

Amanda R. Leonti, MS, Laura Pardo, Todd A. Alonzo, PhD, Robert B. Gerbing, Lisa Eidenschink Brodersen, PhD, Rhonda E. Ries, MA, Jenny L. Smith, MSc, MD, Quy Le, PhD, Richard Aplenc, MD PhD, E. Anders Kolb, MD, John L. Magnani, PhD, William E. Fogler, PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 3772.

https://doi.org/10.1182/blood-2019-124525

Published: 2019

Journal Articles

CBFA2T3-GLIS2 induces Malignant Transformation of Primitive CD34+ Cord Blood Cells and Recapitulates Infant Megakaryocytic Leukemia

Tiffany A. Hylkema, BS, Laura Pardo, Keith R. Loeb, MD, Quy Le, PhD, Suzan Imren, MD, Lisa Eidenschink Brodersen, PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 1444.

https://doi.org/10.1182/blood-2019-126185

Published: 2019

Journal Articles

Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy

Jonathan A Gutman, MD, Prashant Sharma, MD, Enkhtsetseg Purev, MD, Clayton Smith, MD, Amanda Winters, MD PhD, Andrew Hammes, MS, Michael R. Loken, PhD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 4615.

https://doi.org/10.1182/blood-2019-129150

Published: 2019

Journal Articles

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a COG and Target Pediatric AML Study

Jenny L. Smith, MSc, MD, Rhonda E. Ries, MA, Marianne T. Santaguida, BSc, PhD, Christos Gekas, PhD, Todd A Alonzo, PhD, Robert B Gerbing, MA, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, E. Anders Kolb, MD, Tiffany Hylkema, BS, Lisa Eidenschink Brodersen, PhD, Michael R. Loken, PhD, Hamid Bolouri, PhD, Soheil Meshinchi, MD PhD

Blood (2018) 132 (Supplement 1): 881.

https://doi.org/10.1182/blood-2018-99-115544

Published: 2018

Journal Articles

Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance

Blood (2018) 132 (Supplement 1): 5277.

https://doi.org/10.1182/blood-2018-99-114979

Published: 2018

Journal Articles

Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial

Ashkan Emadi, MD PhD, Vu H. Duong, MD, Jeremy Pantin, MD, Mohammad Imran, MD, Rima Koka, MD PhD, Zeba Singh, MBBS, Edward A. Sausville, MD PhD, Jennie Y. Law, MD, Seung Tae Lee, MD PhD, Huidong Shi, PhD, Ravindra Kolhe, MD PhD, Maria R. Baer, MD, Michael R. Loken, PhD, Eugene P. Kennedy, MD, Charles Link, MD, David H. Munn, MD

Blood (2018) 132 (Supplement 1): 332.

https://doi.org/10.1182/blood-2018-99-117433

Published: 2018

Journal Articles

Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531

Laura Pardo, Lisa Eidenschink Brodersen, PhD, Jatinder K Lamba, PhD, Todd A Alonzo, PhD, Yi-Cheng Wang, Dana Paine, Alan S Gamis, MD MPH, E. Anders Kolb, MD, Jessica A. Pollard, MD, Todd M Cooper, DO, Richard Aplenc, MD PhD, Soheil Meshinchi, MD PhD, Michael R. Loken, PhD

Blood (2018) 132 (Supplement 1): 1490.

https://doi.org/10.1182/blood-2018-99-115053

Published: 2018

Journal Articles

Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia

Allison Kaeding, MD, Katherine Tarlock, MD, Sonali Barwe, PhD, Anilkumar Gopalakrisnapillai, PhD, Todd A Alonzo, PhD, Robert B Gerbing, Michael R. Loken, PhD, Rhonda E. Ries, MA, Laura Pardo, Cassie Chou, MD PhD, E. Anders Kolb, MD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 2641.

https://doi.org/10.1182/blood.V130.Suppl_1.2641.2641

Published: 2017

Journal Articles

Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Children's Oncology Group AAML0531 Trial

Lata Chauhan, PhD, Todd A Alonzo, PhD, Jim Wang, Michael R. Loken, PhD, Jessica A. Pollard, MD, Richard Aplenc, MD, Susana C. Raimondi, PhD, Roland B. Walter, MD PhD, Betsy A Hirsch, PhD, Irwin D. Bernstein, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD, Jatinder Lamba, PhD

Blood (2017) 130 (Supplement 1): 2526.

https://doi.org/10.1182/blood.V130.Suppl_1.2526.2526

Published: 2017

Journal Articles

Transcriptomic and Network Signatures of Cryptic Fusion CBFA2T3-GLIS2 in Pediatric AML Reveals Clinical Considerations and Implications

Jenny L. Smith, MSc, MD, Rhonda E. Ries, MA, Heather Louise Schuback, MD, Lisa E. Brodersen, PhD, Michael R. Loken, PhD, Hamid Bolouri, PhD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 1193.

https://doi.org/10.1182/blood.V130.Suppl_1.1193.1193

Published: 2017

Journal Articles

Clinical Implications of Detection and Clearance of Post-Induction Residual Disease in 2119 Children and Young Adults with AML: Children's Oncology Group Studies AAML0531 and AAML1031

Lisa E. Brodersen, PhD, Todd A Alonzo, PhD, Robert B Gerbing, Anders Kolb, MD, Alan S Gamis, MD MPH, Richard Aplenc, MD, Soheil Meshinchi, MD PhD, Michael R. Loken, PhD

Blood (2017) 130 (Supplement 1): 3905.

https://doi.org/10.1182/blood.V130.Suppl_1.3905.3905

Published: 2017

Journal Articles

CD33-Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531 Trial

Jatinder Lamba, PhD, Lata Chauhan, PhD, Miyoung Shin, PhD, Michael R. Loken, PhD, Jessica A. Pollard, MD, Jim Wang, Richard Aplenc, MD, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Roland B. Walter, MD PhD, Irwin D. Bernstein, MD, Alan S Gamis, MD MPH, Todd A Alonzo, PhD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 3826.

https://doi.org/10.1182/blood.V130.Suppl_1.3826.3826

Published: 2017

Journal Articles

Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Todd M Cooper, DO, Rhonda E. Ries, MA, Todd A Alonzo, PhD, Robert B Gerbing, Michael R. Loken, PhD, Lisa E. Brodersen, PhD, Susana C. Raimondi, PhD, Betsy A Hirsch, PhD, Richard Aplenc, MD, Alan S Gamis, MD MPH, Edward A Kolb, MD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 407.

https://doi.org/10.1182/blood.V130.Suppl_1.407.407

Published: 2017

NARROW

Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy

Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol

CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies

Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML

CBFA2T3-GLIS2 induces Malignant Transformation of Primitive CD34+ Cord Blood Cells and Recapitulates Infant Megakaryocytic Leukemia

Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a COG and Target Pediatric AML Study

Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance

Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial

Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531

Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia

Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Children's Oncology Group AAML0531 Trial

Transcriptomic and Network Signatures of Cryptic Fusion CBFA2T3-GLIS2 in Pediatric AML Reveals Clinical Considerations and Implications

Clinical Implications of Detection and Clearance of Post-Induction Residual Disease in 2119 Children and Young Adults with AML: Children's Oncology Group Studies AAML0531 and AAML1031

CD33-Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531 Trial

Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only